Drug-coated balloon versus standard balloon for peripheral artery disease in the leg
Compares a sirolimus-coated balloon with a standard balloon in people with leg artery disease.
Key facts
- Who runs it
- Concept Medical Inc.
- Where
- Singapore, Taiwan, and Thailand20 sites in 3 countriesChoose a country to see its sites
- Trial code
- Registry title
- Sirolimus Coated Balloon Versus Standard Balloon for SFA and Popliteal Artery Disease
- Status
- Recruiting
- People taking part
- 279 people, planned
- Started
- 8 Sept 2020
- Expected to end
- Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- MagicTouch PTA sirolimus drug coated balloon (DCB)
- POBA standard balloon
- Record updated
- 3 July 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with narrowed or blocked arteries in the thigh and behind the knee (superficial femoral and popliteal arteries). It compares a sirolimus coated balloon with a standard balloon.
- Age
- 21 years or older
- Sex
- All sexes can join
- Disease stage
- Rutherford class 3 to 6 in the treated leg. New or re-narrowed lesions (more than 50% narrowing or blocked) from 2 to 20cm (0.8–7.9 in) long. At least one open lower-leg artery with blood flow to the foot.
- Earlier treatment
- People cannot join if they had bypass surgery of the target artery or a stent already placed in the target lesion.
Main reasons for not taking part
- Other illness limiting life expectancy to 1 year or less
- Pregnant or planning pregnancy during the study
- Heel gangrene or planned amputation of the treated leg
- Bleeding problems or stomach ulcers that prevent use of clopidogrel or aspirin
- Known allergy to sirolimus
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Age ≥ 21 years or minimum age
- Rutherford class 3 to 6 in the target limb; Intraoperative Inclusion Criteria
- Single or sequential de novo or re-stenotic lesions (stenosis of > 50% or occlusions) from 2 to 20cm in the femoropopliteal arteries. Lesion is considered as one lesion if there is maximum of 30mm gap between lesions at discretion of investigator. Femoropopliteal arteries are superficial femoral artery, popliteal artery P1 and P2
- Inflow free from flow limiting lesions (<50% stenosis) confirmed by duplex or angiography. Subjects with flow limiting inflow lesions (>50% stenosis) can be included if lesion had been treated successfully (<30% residual stenosis) before or during the index procedure
- At least one non-occluded crural vessel (ie. without significant stenosis) with angiographically documented run off to the foot
Who cannot take part
- Subject is currently participating in another investigational drug or device study that has not reached first primary endpoint yet
- Prior bypass surgery of target vessel
- Previously implanted stent in the target lesion
- Use of DCBs, drug eluting stent, specialty balloons or artherectomy devices during the index procedure. (Non-compliant balloons are not considered specialty balloons)
- Comorbid conditions limiting life expectancy ≤ 1 year
- Bleeding diathesis or another disorder such as gastrointestinal ulceration which restrict the use of clopidogrel or aspirin
- Known allergy to sirolimus; Intraoperative Exclusion Criteria
- Failure to successfully cross the target lesion with a guide wire (successful crossing means tip of the guide wire distal to the target lesion in the absence of flow limiting dissections or perforations)
- Failure to obtain <30% residual stenosis in a pre-existing lesion
- Subject is pregnant or planning to become pregnant during the course of the study
- Heel gangrene
- Planned amputation of the target limb
- Vulnerable or protected adults
- Highly calcific lesions
- Lesions requiring retrograde access (SAFARI)
This trial has no sites in United States.
It has sites in 3 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study aims to conduct a randomized, double blind, randomised controlled multicentre trial of sirolimus drug coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial and popliteal arterial disease.
The 2 groups in the trial
- MagicTouch PTA sirolimus drug coated balloon (DCB)Treatment being tested
MagicTouch PTA sirolimus drug coated balloon (DCB) in addition to standard balloon angioplasty
- Placebo balloon angioplastyExisting treatment, for comparison
Placebo balloon angioplasty in addition to standard balloon angioplasty (PTA)
Treatment: POBA standard balloon
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Randomized Controlled Trial of First Sirolimus Coated Balloon Versus Standard Balloon Angioplasty in The Treatment of Superficial Femoral Artery and Popliteal Artery Disease
- Plain-language title
- Drug-coated balloon versus standard balloon for peripheral artery disease in the legGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 3 July 2025